Cytokinetics Inc (CYTK) is ready for next Episode as it posted an annual sales of 18,470 K

On Tuesday, Cytokinetics Inc (NASDAQ: CYTK) was -3.63% drop from the session before settling in for the closing price of $44.91. A 52-week range for CYTK has been $40.53 – $75.71.

Annual sales at Healthcare sector company grew by 44.31% over the past five years. When this article was written, the company’s average yearly earnings per share was at -8.67%. With a float of $115.45 million, this company’s outstanding shares have now reached $118.21 million.

Let’s look at the performance matrix of the company that is accounted for 498 employees. In terms of profitability, gross margin is -890.46%, operating margin of -2902.72%, and the pretax margin is -3191.11%.

Cytokinetics Inc (CYTK) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cytokinetics Inc stocks. The insider ownership of Cytokinetics Inc is 2.50%, while institutional ownership is 109.87%. The most recent insider transaction that took place on Mar 18 ’25, was worth 87,160. In this transaction EVP Research & Development of this company sold 2,000 shares at a rate of $43.58, taking the stock ownership to the 140,455 shares. Before that another transaction happened on Mar 17 ’25, when Company’s EVP, Chief Commercial Officer sold 2,775 for $44.38, making the entire transaction worth $123,154. This insider now owns 34,888 shares in total.

Cytokinetics Inc (CYTK) Performance Highlights and Predictions

According to the Wall Street analysts, stocks earnings will be around -8.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.31% during the next five years compared to -20.02% drop over the previous five years of trading.

Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators

You can see what Cytokinetics Inc (CYTK) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 277.47.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.28, a number that is poised to hit -1.37 in the next quarter and is forecasted to reach -4.64 in one year’s time.

Technical Analysis of Cytokinetics Inc (CYTK)

Cytokinetics Inc (NASDAQ: CYTK) saw its 5-day average volume 1.35 million, a negative change from its year-to-date volume of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 65.19%. Additionally, its Average True Range was 2.32.

During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 14.58%, which indicates a significant decrease from 20.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.85% in the past 14 days, which was lower than the 47.99% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $46.31, while its 200-day Moving Average is $51.78. Nevertheless, the first resistance level for the watch stands at $44.35 in the near term. At $45.43, the stock is likely to face the second major resistance level. The third major resistance level sits at $46.17. If the price goes on to break the first support level at $42.53, it is likely to go to the next support level at $41.79. Assuming the price breaks the second support level, the third support level stands at $40.71.

Cytokinetics Inc (NASDAQ: CYTK) Key Stats

There are 118,411K outstanding shares of the company, which has a market capitalization of 5.12 billion. As of now, sales total 18,470 K while income totals -589,530 K. Its latest quarter income was 16,930 K while its last quarter net income were -150,020 K.